PDL Biopharma (NASDAQ:PDLI) is trading near a 52-week high, and its share price has appreciated more than 30% year to date. This company's revenue comes from licensing its valuable intellectual property to biotech and pharma companies including Roche, Biogen Idec, and Eli Lilly. PDL Biopharma certainly has a unique business model, but it's perhaps known best by investors for its whopping 7.3% dividend yield.
In the following video, health care analyst Max Macaluso and bureau chief Brenton Flynn discuss both the opportunities and risks that face this stock.
Max Macaluso, Ph.D., Brenton Flynn, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Caveat Emptor When Buying High-Yield Drug Stocks
High-yielding pharma and biotech stocks should probably come with a warning label.
Why Transocean, Outfront Media, and PDL BioPharma Jumped Today
Despite a down market, these stocks gained ground. Find out why.
Here's Why PDL BioPharma Inc. Is Soaring Today
Investors are cheering an incredible profit improvement announced Thursday afternoon. But there's a good reason they aren't cheering more loudly.